Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer

NCT02355119 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

310

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: FOLFOXIRI
DRUG: Gemcitabine

Sponsor

Azienda Ospedaliero, Universitaria Pisana